reports
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Hilde Van Boxstael
- Thomas Couvreur
- Thomas Vranken
- Thomas Vranken
Hyloris FIRST LOOK: Pipeline extends into veterinary medicine
Hyloris adds a new asset to the pipeline that is geared toward veterinary medicine. HY-095 is long-acting injectable formulation of a well-known proton pump inhibitor for the treatment of equine gastric ulcer syndrome, allowing more reliable drug delivery and lower dosing frequency vs. existing orals. Together with its partner, Hyloris will fund development costs and manage clinical trials in exchange for a 90%/10% profit sharing. We reiterate our € 5 TP and Hold rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Hyloris Governance overhang weighs down the case
Following the FSMA statements and outcome of the independent forensic investigation of the QliniQ transactions, Hyloris will initiate a transition process to a new CEO, and the CFO and CLO will step down. Last week, the stock resumed trading (-75% intraday) following publication of the 2023 annual report, which included a qualified opinion regarding the Pleco agreement. Additionally, the QliniQ transactions case has been referred to the public prosecutor's office. We took a step back to evaluate...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Hyloris FIRST LOOK: Management step down after conclusion of forensic ...
Hyloris provided an update following completion of the independent forensic investigation with respect to the QliniQ transactions. While management dispute the findings of the independent forensic review, they have proposed to step down from their roles in the interest of the company. In addition, we welcome the board's decision to strengthen Hyloris' governance, which in our view will contribute to building investor trust going forward. This aside, we continue to believe in the business case, a...
- Jacob Mekhael
- Kristof Samoy
- Thomas Vranken
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Laura Roba
Hyloris Pharma - Shares suspended pending 2023 audit and forensic revi...
KPMG informed the Audit committee that additional work is required to finalize the 2023 audit. They initiated a forensic independent review regarding the Qliniq transaction, including internal communication and documentation practices. Pending the review, shares will remain suspended.The Company does not expect to change the restated accounting treatment related to the Qliniq transactions.TP and BUY rating reiterated as we believe the current share price is not fully reflective of the pipeline p...
- David Seynnaeve
- PhD
Hyloris Pharma - Post-FY23 model revisions
*HYL's recent FY23 publication indicated 1/ a 44% increase YoY in its product revenue with significant further ramp-up expected in ‘24 with at least doubling of product revenue (mainly driven by commercial rollout of Maxigesic IV in the USA) and 2/ further increase in R&D expenses in ‘24.*As a result thereof and based on more in-depth analysis of the value proposition of each asset, we 1/ finetuned revenue & cost estimates for the coming years and 2/ aligned the clinical and commercial stra...
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
Hyloris Moving ahead with clinical and regulatory progress
Hyloris has made clinical and regulatory progress in the last 12 months, most notably the FDA approval for Combogesic IV in the US. In addition, the company has made a number of new product announcements expanding its pipeline to 18 reformulated and repurposed products, and 3 generics. Hyloris continues to aim for 30 products by 2025, which means we should expect an eventful period in terms of new product announcements. We summarise Hyloris' progress, and revamp our model to incorporate the new ...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.